webleads-tracker

Home  >  MEDTECH  > Trinean to enter into global supply agreement with QIAGEN...
  >  MEDTECH
Jan 24th, 2014
 
Trinean to enter into global supply agreement with QIAGEN
 
Trinean to manufacture and supply the QIA xpert–a micro-volume spectrometer for DNA and RNA quantitation and quality analysis.
Send to a friend

Trinean, the leading provider of microfluidic spectrophotometry platforms, announced that it entered into a manufacturing and supply agreement with QIAGEN for the production of the QIA xpert, a micro-volume spectrometer for DNA and RNA quantitation and quality analysis. This platformis aUV/VIS spectrophotometer which contains tailor-made solution for QIAGEN customers using QIAGEN’s DNA and RNA sample technologies and devices for quality control applications.

We are very pleased with this agreement between QIAGEN and Trinean,” comments Philippe Stas, CEO of Trinean. "Adoption of our technology by QIAGEN, the market leader in DNA and RNA sample technologies, is an important new step in the global validation of our innovative take on UV-VIS spectroscopy.”

Quality control (QC) is becoming increasingly important in nucleic acid based testing as novel detection technologies become more and more sensitive.” Dietrich Hauffe, Senior VP,Head of Business Area Life Sciences at QIAGEN adds. “The QIAxpert system provides a unique combination of accurate quantification and the capability to discriminate between molecules of interest. The system allows us to match high-performance sample technologies, in particular isolation, extraction and purification with high-speed spectrophotometry for confirmatory purposes. It will contribute to superior data output across all analytical workflows using DNA or RNA, from PCR to next generation sequencing. QIAxpert can also allow our customers to make better informed decisions with regards to usage of samples in subsequent downstream processes, reducing the risk of repeat experiments. These benefits can result in significant time and cost savings while at the same time increasing the quality of data output with significant advantages in research, applied and clinical markets.

This agreement significantly boosts the market reach of our spectrometry technology”, said Yvan Sergeant, VP Commercial Operations of Trinean. “It combines microfluidics with innovative spectral content profiling software for accurate quantitation of biological samples and further illustrates the importance of our ability to have a sound purity check of biological samples prior to any genetic test.”

The QIAxpert is a customized version of the Xpose reader, launched by Trinean early 2013.The platform redefines manual UV/VIS quantification into a convenient, high speed solution.The drop and read approach avoids time-consuming sample loading and cleaning steps thereby minimizing the hands-on time on the reader. The full-color touch screen gives single touch access to advanced analytical software,including dye-free specific quantification of DNA, RNA or protein in samples containing interfering components, using Trinean’s proprietary algorithms for UV/VIS spectral deconvolution.

About Trinean

Trinean is a Belgium based instrumentation company, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes two instruments, the Xpose for ‘Touch & Go’ biomolecule quantification and the DropSense96®, analyzing up to 96 samples, using microfluidic chips for standardized sample analysis ( DropPlates and Xpose Slides). The Trinean platform is complemented with a software toolbox for improved data interpretation and lab-automation.

For more information about Trinean, visit http://www.trinean.com

About Qiagen

QIAGEN N.V. is a Dutch holding company publically traded on NASDAQ and Frankfurt Prime Standard. The Company is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular insights. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human - 3 healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2013, QIAGEN employed more than 4,100 people in over 35 locations worldwide.

Further information can be found at http://www.qiagen.com

 

 
More MEDTECH news

Jul 17th
Jul 17th
Jul 16th
Jul 12th
Jul 8th
 
©2007 Yole Developpement All rights reserved                  Disclaimer | Legal notice | To advertise
Yole Développement: Le Quartz, 75 cours Emile Zola, 69100 Villeurbanne, France. TEL: (33) 472 83 01 80 FAX: (33) 472 83 01 83 E-Mail: info @yole.fr